Sphingolipids in Cerebrospinal Fluid and Plasma Lipoproteins of APOE4 Homozygotes and Non-APOE4 Carriers with Mild Cognitive Impairment versus Subjective Cognitive Decline-Reference-Cited by-同舟云学术

Sphingolipids in Cerebrospinal Fluid and Plasma Lipoproteins of APOE4 Homozygotes and Non-APOE4 Carriers with Mild Cognitive Impairment versus Subjective Cognitive Decline

Published:2023-05-03 Issue:1 Volume:7 Page:339-354
ISSN:2542-4823
Container-title:Journal of Alzheimer's Disease Reports
language:
Short-container-title:ADR

Author:

den Hoedt Sandra¹,Dorst-Lagerwerf Kristien Y.¹,de Vries Helga E.²,Rozemuller Annemieke J.M.³,Scheltens Philip⁴,Walter Jochen⁵,Sijbrands Eric J.G.¹,Martinez-Martinez Pilar⁶,Verhoeven Adrie J.M.¹,Teunissen Charlotte E.⁴,Mulder Monique T.¹

Affiliation:

1. Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands

2. Department of Molecular Cell Biology and Immunology, Amsterdam Neuroscience, Amsterdam University Medical Center, Free University Amsterdam, The Netherlands

3. Department of Pathology, Amsterdam Neuroscience, Amsterdam University Medical Center, Free University Amsterdam, The Netherlands

4. Department of Clinical Chemistry, The Alzheimer Center Amsterdam, and Neurochemistry Laboratory, Amsterdam Neuroscience, Amsterdam University Medical Center, Free University Amsterdam, The Netherlands

5. Department of Neurology, University of Bonn, Bonn, Germany

6. Department of Neuroscience, School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands

Abstract

Background: Alzheimer’s disease (AD) patients display alterations in cerebrospinal fluid (CSF) and plasma sphingolipids. The APOE4 genotype increases the risk of developing AD. Objective: To test the hypothesis that the APOE4 genotype affects common sphingolipids in CSF and in plasma of patients with early stages of AD. Methods: Patients homozygous for APOE4 and non-APOE4 carriers with mild cognitive impairment (MCI; n = 20 versus 20) were compared to patients with subjective cognitive decline (SCD; n = 18 versus 20). Sphingolipids in CSF and plasma lipoproteins were determined by liquid-chromatography-tandem mass spectrometry. Aβ42 levels in CSF were determined by immunoassay. Results: APOE4 homozygotes displayed lower levels of sphingomyelin (SM; p = 0.042), SM(d18:1/18:0) (p = 0.026), and Aβ42 (p < 0.001) in CSF than non-APOE4 carriers. CSF-Aβ42 correlated with Cer(d18:1/18:0), SM(d18:1/18:0), and SM(d18:1/18:1) levels in APOE4 homozygotes (r > 0.49; p < 0.032) and with Cer(d18:1/24:1) in non-APOE4 carriers (r = 0.50; p = 0.025). CSF-Aβ42 correlated positively with Cer(d18:1/24:0) in MCI (p = 0.028), but negatively in SCD patients (p = 0.019). Levels of Cer(d18:1/22:0) and long-chain SMs were inversely correlated with Mini-Mental State Examination score among MCI patients, independent of APOE4 genotype (r< –0.47; p < 0.039). Nevertheless, age and sex are stronger determinants of individual sphingolipid levels in CSF than either the APOE genotype or the cognitive state. In HDL, ratios of Cer(d18:1/18:0) and Cer(d18:1/22:0) to cholesterol were higher in APOE4 homozygotes than in non-APOE4 carriers (p = 0.048 and 0.047, respectively). Conclusion: The APOE4 genotype affects sphingolipid profiles of CSF and plasma lipoproteins already at early stages of AD. ApoE4 may contribute to the early development of AD through modulation of sphingolipid metabolism.

Publisher

IOS Press

Subject

Psychiatry and Mental health,Geriatrics and Gerontology,Clinical Psychology,General Neuroscience

Reference72 articles.

1. Alzheimer’s disease;Scheltens;Lancet,2021

2. Dementia prevention, intervention, and care;Livingston;Lancet,2017

3. Mild cognitive impairment;Petersen;Continuum (Minneap Minn),2016

4. Amsterdam Dementia Cohort: Performing research to optimize care;van der Flier;J Alzheimers Dis,2018

5. Diagnostic accuracy of blood biomarkers for Alzheimer’s disease and amnestic mild cognitive impairment: A meta-analysis;Chen;Ageing Res Rev,2021